Eribulin Mesylate(CAS: 441045-17-6)

Eribulin Mesylate is a semi-synthetic analog of dolastatin 10, a naturally occurring compound with potent anti-cancer properties. It is used in the treatment of metastatic breast cancer and peripheral T-cell lymphoma. The compound has a molecular formula of C33H41N3O7S and belongs to the class of macrolides.

Eribulin Mesylate is primarily used as an antineoplastic agent in the treatment of metastatic breast cancer and peripheral T-cell lymphoma. It works by inhibiting microtubule dynamics, leading to cell cycle arrest and apoptosis in cancer cells.

Eribulin Mesylate is generally considered safe when used under medical supervision. However, it can cause side effects such as peripheral neuropathy, fatigue, and nausea. Patients should follow medical advice and take necessary precautions to avoid adverse reactions.

Eribulin Mesylate should be stored in a tightly sealed container at 15°C to 30°C (59°F to 86°F). It should be protected from light and kept away from heat sources. The drug should be handled with care to avoid exposure to skin or mucous membranes.